Sagent Pharmaceuticals

Sagent Pharmaceuticals is focused on developing, manufacturing, sourcing and marketing pharmaceutical products. The Company offers its customers a broad range of products across anti-infective, oncology and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. Sagent generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience.

Type
Subsidiary
HQ
Schaumburg, US
Founded
2006
Sagent Pharmaceuticals was founded in 2006 and is headquartered in Schaumburg, US

Sagent Pharmaceuticals Office Locations

Sagent Pharmaceuticals has an office in Schaumburg
Schaumburg, US (HQ)
1901 N. Roselle Road

Sagent Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2006

Total Funding

$70 m
In total, Sagent Pharmaceuticals had raised $70 m

Sagent Pharmaceuticals Financials

Sagent Pharmaceuticals's revenue was reported to be $318.3 m in FY, 2015
USDFY, 2013FY, 2014FY, 2015

Revenue

244.8 m289 m318.3 m

Revenue growth, %

18%10%

Cost of goods sold

167.2 m202.8 m230.6 m

Gross profit

77.5 m86.2 m87.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016

Revenue

60.8 m70.9 m69.2 m65.4 m82.6 m77.3 m75.2 m67.8 m71.7 b

Cost of goods sold

42.3 m50.5 m46.6 m46.6 m60.7 m58.9 m50.8 m50.9 m54.4 b

Gross profit

18.6 m20.4 m22.6 m18.8 m21.9 m18.4 m24.4 m16.8 m17.4 b

Gross profit Margin, %

31%29%33%29%27%24%32%25%24%
USDFY, 2013FY, 2014FY, 2015

Cash

42.3 m55.6 m29 m

Inventories

6.5 m5.6 m7.4 m

Current Assets

235.8 m198.5 m191.6 m

PP&E

57.7 m71.2 m19.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016

Cash

45.9 m25.7 m47.8 m136.3 m49.4 m50.9 m25.9 m12.5 m15.5 m

Inventories

48.6 m44.2 m43.2 m43.3 m61.6 m71.7 m76.2 m83.4 m86.5 m

Current Assets

240 m227.1 m233.3 m239.8 m205.5 m206.4 m185.6 m177.4 m185 m

PP&E

57.9 m56.7 m56.9 m56.9 m69.8 m70.3 m68.2 m23.7 m28.3 m
USDFY, 2013FY, 2014FY, 2015

Net Income

29.6 m39.9 m(21.9 m)

Depreciation and Amortization

7.1 m9.5 m13.7 m

Accounts Receivable

8.6 m(16 m)(9.3 m)

Inventories

(3.5 m)2.2 m(2.6 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

2.8 m5.1 m3.1 m1.9 m(1.9 m)
Show all financial metrics

Sagent Pharmaceuticals's Web-traffic and Trends

Sagent Pharmaceuticals Company Life and Culture

You may also be interested in